SpringerLink
Log in

Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy

  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11: 891–905.

    Article  CAS  PubMed  Google Scholar 

  2. Zampetti A, Silvestri G, Manco S, et al. Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study. J Am Acad Dermatol 2015; 72: 85–91.

    Article  PubMed  Google Scholar 

  3. Campanati A, Giannoni M, Buratti L, et al. Skin features in myotonic dystrophy type 1: an observational study. Neuromuscul Disord 2015; 25: 409–13.

    Article  CAS  PubMed  Google Scholar 

  4. Nakai K, Yoneda K, Maeda R, et al. Giant pilomatricoma and psoriasis vulgaris with myotonic dystrophy. Eur J Dermatol 2009; 19: 507–8.

    PubMed  Google Scholar 

  5. Grounds MD, Torrisi J, Anti-TNFalpha J. (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004; 18: 676–82.

    Article  CAS  PubMed  Google Scholar 

  6. Ermolova NV, Martinez L, Vetrone SA, et al. Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul Disord 2014; 24: 583–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mammarella A, Ferroni P, Paradiso M, et al. Tumor necrosis factoralpha and myocardial function in patients with myotonic dystrophy type 1. J Neurol Sci 2002; 20: 59–64.

    Article  Google Scholar 

  8. Theibich A, Dreyer L, Magyari M, Locht H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol 2014; 33: 719–23.

    Article  PubMed  Google Scholar 

  9. Krueger GG, Langley RG, Leonardi C, et al. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. N Engl J Med 2007; 356: 580–92.

    Article  CAS  PubMed  Google Scholar 

  10. Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37: 413–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan

    Yasuyuki Fujita, Satoru Shinkuma, Toshifumi Nomura & Hiroshi Shimizu

Authors
  1. Yasuyuki Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Shinkuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshifumi Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuyuki Fujita.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujita, Y., Shinkuma, S., Nomura, T. et al. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy. Eur J Dermatol 26, 187–188 (2016). https://doi.org/10.1684/ejd.2015.2688

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2015.2688

Search

Navigation